The US develops a vaccine to deal with a new CoV strain
The US company Novavax developed the Covid-19 vaccine that was 89.3 percent effective in the Phase Three trial in the UK, but at a lower rate with the South African strain.
continue reading
The US company Novavax developed the Covid-19 vaccine that was 89.3 percent effective in the Phase Three trial in the UK, but at a lower rate with the South African strain.
continue reading
